INTRODUCTION
As of 1 February 2017, 20 years after California [1] became the first US state authorizing medical marijuana (MM), 27 states and the District of Columbia have MM laws, enacted through ballot initiatives or legislation, or both. Many of these laws have evolved in response to local experience and the federal government's changing and often uncertain policy on MM [2] . While the federal Controlled Substances Act (CSA) of 1970 continues to classify marijuana as a Schedule I drug with no acceptable medical use and high potential for abuse [3, 4] , the Obama administration adopted a position of non-interference [5] , and Congress has prohibited the Department of Justice from interfering with states implementing medical marijuana laws [6, 7] . It is uncertain whether the Trump administration will maintain this non-interference policy. Regardless, federal law has important effects beyond the risks of prosecution.
MM proponents contend that federal MM prohibition reduces clinicians' treatment options and patients' access to MM, hinders research efforts to evaluate MM rigorously, runs counter to high levels of clinician and public support for legalizing MM [8] [9] [10] and ignores evidence of its therapeutic benefit for treating certain health conditions [11] [12] [13] [14] . Less discussed has been the unusual regulatory vacuum the federal legal status creates for MM. Unlike other medicines, MM has not undergone the Food and Drug Administration (FDA) approval process, and is not subject to the associated rules on drug efficacy testing, safety monitoring, labeling and marketing. The therapeutic use of marijuana is not subject to the strictures that apply to other scheduled medicines covered by the CSA, such as the requirement of a federal prescribing license and rules on supply chain security and accountability. While patient information, including prescriptions, is covered by federal patient privacy rules [15] , not all MM is provided as under prescription and it is unclear if this federal privacy protection applies to an illegal drug. Patients using MM are not protected from discrimination under the Americans with Disabilities Act, which does not prohibit discrimination based on current use of illegal use of drugs [16] .
In the absence of the usual federal regulations of controlled medicines, states are left to develop their own substitutes-or not. States traditionally regulate the marketing and use of legal drugs-tobacco and alcohol-that can cause harm to users and others. Perhaps because of this experience, and concerns about federal interference, early state MM laws typically covered matters that they had already dealt with in the realms of tobacco and alcohol (e.g. restrictions on use by minors and restrictions on advertising) [2] . As patients' needs for a clearly defined dose of an uncontaminated product became more apparent, and the federal non-interference policy took shape, state MM laws began to address FDA-type issues explicitly, such as source and product safety [2, 17] . In this new area of health policy, states are again serving as 'laboratories of democracy' [18] , but scientists evaluating these laws have focused upon spillover effects of MM on recreational use and its harms [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] , rather than on the ability of states to regulate marijuana effectively as a medicine.
There is tremendous interest in understanding the impact of these laws on the community. To assess impact, however, one must first have a clear understanding of what the law actually purports to allow or enable. Secondly, one must also have a clear understanding of how the written law is being implemented or interpreted by the agents empowered by the law, and obeyed by those subject to it. Finally, one must have good measurement of an outcome that is influenced meaningfully by the law. This paper provides unprecedented clarity on the first step-the law as it is written-by providing the first detailed scientific mapping of specific provisions of MM laws on the books at a particular point in time. As the discussion of medical and recreational marijuana laws have become blurred, previous analyses of the impacts of medical marijuana laws remain limited in their consideration of dimensions of these laws [31] [32] [33] . With few exceptions [19, 22] , studies of MM laws have grouped states as MM versus non-MM [20, 21, [23] [24] [25] [26] [27] [28] [29] [30] , ignoring the potentially important legal differences among MM states that can influence how the medical marijuana market operates, its size and the likelihood that spillover effects to the non-medical market occur.
This study sheds new light by providing greater detail of the variation that exists in terms of the laws on the books across the 50 states and Washington DC as they pertain to patient protections and requirements, product safety and dispensary regulation. It shows how these states' approaches compare to the standard Federal approach, identifying the degree to which particular states adopted a true 'medical' approach to their law. It therefore lays the groundwork for studies evaluating implementation, compliance and evaluating the potential impacts of these laws on medical access, non-medical use, benefits and harm.
METHODS
Two legal researchers at the Public Health Law Research national program office of the Robert Wood Johnson Foundation systematically collected and redundantly coded state MM laws effective on 1 January 2014 to create three empirical legal data sets: rules for patients, product safety and dispensaries. A third legal researcher oversaw the research and implemented quality control protocols. The data sets were subsequently extended back to 1 July 2009 and updated to 2017 by legal researchers of the Prescription Drug Abuse Policy System (PDAPS), using the same methods. This study presents cross-sectional analyses of laws in effect on 1 February 2017.
State laws were included if they established comprehensive MM programs permitting the use of marijuana for medicinal purposes without restriction based on tetrahydrocannabinol (THC) level. THC is the psychoactive component of cannabis. Included programs remove criminal penalties for the use of MM by patients diagnosed with a qualifying disease as determined by state law. States with laws allowing limited use of MM-such as the authorizing of cannabidiol (CBD, the plant extract and non-psychoactive extract component of cannabis), hemp extract or low-THC cannabis preparations-were coded as not authorizing use of MM.
State laws were identified using keyword searches and table-of-contents review on Westlaw and LexisAcademic, HeinOnline and state-specific legislative websites. Redundant research and comparison with secondary sources (the website http://medicalmarijuana.procon.org/ Archived at http://www.webcitation.org/6rjtkBmru on 5 June 2017 and the National Conference of State Legislatures) were used to verify that all relevant laws and regulations were collected. The legal researchers analyzed samples of the collected legal texts to define a list of variables and create coding schemes, under the guidance of an expert in MM policy (R.P.). Using an iterative process designed to produce stable, accurate and reproducible observations [34, 35] , statutes and regulations were coded redundantly by the legal researchers in batches of 10 states using MonQcle ™ policy surveillance software (http://www.
Monqcle.com/; Archived at http://www.webcitation.org/ 6qv5N1u0I on 2 June 2017). Coding was compared by the supervisor at the end of each batch, and a divergence rate was calculated (total no. of divergent codes/total records coded by one coder). The team then met and the discrepancies were discussed and attributed to coder error, ambiguous coding questions or ambiguous legal texts. Corrections, question revisions and coding conventions were made as necessary and recorded in the research protocols. Once a coding batch achieved a discrepancy rate of < 5%, only 20% of records were coded redundantly in succeeding batches. Researchers conducted a final statistical quality check (SQC) of a randomly selected set of variables based on an expected error rate of 20%. The SQC error rates were: 2.6% (rules for qualifying patients), 2.25% (product safety) and 1.42% (dispensaries). Full longitudinal data sets, codebooks and protocols describing the methods in detail are available on the Prescription Drug Abuse Policy System (PDAPS) website (http://www.pdaps.org/; Archived at http://www.webcitation.org/6qv5CZNaZ on 2 June 2017). A fourth data set, not included in this study, contains state-level laws regulating marijuana care givers and is also available on the PDAPS website.
RESULTS
As of 1 February 2017, lawmakers in 27 states and Washington, DC (55% of states) have legalized MM use in comprehensive programs ( Fig. 1) . (We will include Washington, DC within the count of 'states' for the remainder of this paper, and the denominator for the percentages reported will be 28, the number of states that have legalized MM.) MM states are clustered in the northeast, east north central and western United States. Florida and Arkansas are the only southern states that have legalized MM. Legislators in several southern states have passed laws allowing for low THC and high CBD strains of marijuana to be used for medicinal purposes, but these laws do not meet our definition of a comprehensive MM scheme. State MM laws address patient registration; qualifying diseases and symptoms; patient privacy and discrimination protections; cultivation; use restrictions; product testing; distribution site features; waste protocols; packaging/labeling requirements; dispensary density and zoning restrictions; dispensary product supply sources; and dispensary stock amount limits. Details of current laws addressing each of these dimensions are included in Table 1 .
Patient registration and civil rights laws
Although not a common element of early laws adopted before 2009, when the US Department of Justice first articulated explicit guidelines for limited federal toleration of state MM laws [36] , by February 2017 all states except Florida require MM patient registration ( and youth centers (11 states, 39%). Five states (18%) bar any use in the presence of a minor. Other restricted locations include correctional facilities (20 states, 71%) and licensed drug treatment facilities (four states, 14%). Five states (18%) limit use in health-care facilities.
Product safety, labeling and packaging
Most states have laws requiring some form of product safety testing (22 states, 79%), which can include contaminant and/or pesticide testing and/or cannabinoid profiling. Eighteen (64%) states require some type of testing of all MM products before they may be sold. The remaining four (14%) states only require testing at the request of the state regulatory agency following complaint or reason to believe contamination has occurred. In the absence of federal guidance, standards for testing can and do differ. It should also be noted that this is safety testing of the product itself. No states have tested, nor require tests on, the safety of MM in vivo, despite a limited evidence base on how MM is metabolized, how it interacts with other medicines or whether it poses higher risks for certain patient populations [12, 13] .
Nearly all MM states have product labeling requirements (23 states, 82%), but there is little consistency in the labeling requirements themselves. Labeling rules in state law include listing the amount of usable marijuana (20 states, 71%), product potency (20 states, 71%), dispensary identification (17 states, 61%), strain of marijuana (nine states, 32%), ingredients for edibles (12 states, 43%), warning for medical use only (12 states, 43%), warning to abstain from operating machinery (11 states, 39%), health risks (10 states, 36%), proof of contaminant testing (seven states, 25%), lack of FDA approval (six states, 21%), compliance with other federal or state law(s) (seven states, 25%) and instructions for use (six states, 21%).
Twenty-one (75%) states regulate MM packaging but, as with labeling, the rules vary. Requirements include tamper-proof packaging (14 states, 50%), child-proof (or child-resistant) packaging (15 states, 54%), opaque packaging (nine states, 32%), compliance with federal or state laws (six states, 21%), plain packaging (five states, 18%) and re-closable packaging (four states, 14%). Nineteen (68%) states have product packaging (trade dress) restrictions, including anything typically designed to attract minors (14 states, 50%), 'false or misleading' statements (13 states, 46%), cartoons (11 states, 40%), depictions of minors (eight states, 29%), pictures of marijuana (six states, 21%), packaging that resembles that of candy (six Dispensary location is also commonly regulated or designated for local regulation. Twenty (71%) states permit local zoning restrictions on dispensaries and 18 (64%) states limit the total number of dispensaries allowed to operate within the state. Twenty-one (75%) states have a restriction on dispensary location. The most common location restrictions for dispensaries were based on proximity to schools (20 states, 71%) and daycare facilities (11 states, 39%). Other facilities triggering dispensary location restrictions included churches (six states, 21%), colleges (Colorado), recreational centers (District of Columbia, Nevada and Washington), group care homes (Illinois), drug-treatment facilities (Colorado) and other dispensaries (Oregon). Departments assigned regulatory oversight over dispensaries include health departments (AZ, DC, DE, HI, IL, MA, ME, MN, NJ, NH, NM, NY, NV, OR, PA, RI), Consumer Protection (CA, CT), Licensing and Regulatory Affairs (MI), Revenue (CO), Public Safety (VT) and Board of Pharmacy (OH).
Twenty-four (86%) states have explicit structural requirements for dispensaries and/or other facilities in the MM supply chain, such as cultivation and distribution sites. Related both to safety and security, these include maintaining a security system (21 states, 75%), using secure, locked spaces accessible only to cardholders and/or authorized employees (18 states, 64%), hand-washing stations (10 states, 36%) and/or ventilation systems (six states, 21%). Twenty-one (75%) states have waste disposal regulations. These include requirements to keep a record of waste disposal (19 states, 68%), destroy waste (16 states, 57%), transfer waste to law enforcement (five states, 18%) or deliver waste to a state agency (Connecticut).
DISCUSSION
State MM laws allow the therapeutic use of a drug that has not been tested for safety and efficacy under FDA rules. Unlike FDA-approved medications, there is no assurance of national standardization in the doses and ingredients, or that the products have been manufactured in safe conditions. Patients being treated with FDA-approved prescription drugs in conventional health-care settings enjoy some protection under federal law of their privacy and from discrimination based on their use of a drug to treat a disability. To prevent counterfeiting and diversion, controlled medicines are tracked strictly from factory to pharmacy, and physicians who prescribe controlled substances are required to have a special license to do so. None of these taken-for-granted national regulatory assurances apply to MM. The federal refusal to adjust the scheduling of marijuana has resulted in a state patchwork quilt of differing and even conflicting rules to fill the gap.
States are also legislating to address the risk of social side effects from MM sale and use, such as traffic accidents due to 'drugged driving', increased emergency room visits and improper youth access [37] [38] [39] [40] [41] . Legislators are drawing upon regulatory models developed to control alcohol and tobacco [42] . As with state plugging of federal regulatory gaps, there is little consistency in the detailed requirements or the assignment of monitoring and enforcement authority. Whether and how the laws are actually enforced was not evaluated here, but implementation studies are an important next step for researchers.
More than half the states have decided that marijuana should be available for therapeutic purposes. The link between MM and a political movement to reduce or eliminate legal restrictions on recreational marijuana is beyond the scope of this study. We can say that all eight states that have adopted legalization policies as of January 2017 were states that previously allowed medical marijuana [43] and had decriminalization policies in place for non-medical use [2] .
State MM laws, whatever their impetus, have tried to varying degrees to address the regulatory hole created by the inability of the FDA to regulate this medication nationally. Serious deficiencies in these state efforts would add to the rationale for federal rescheduling and the integration of marijuana into the standard controlled substances and pharmaceutical regulatory framework. Conversely, if states are able to successfully manage the safe use and distribution of a new pharmaceutical product, critics of federal oversight of the pharmaceutical industry would have an interesting case study to ponder.
The best approach to protecting patients and the public from the risks associated with MM is still unknown, as research is only now documenting in detail the differences across states in their regulatory approaches. Work is also ongoing to document important local-level regulatory variation. More work is needed to document the extent to which the variation in laws on the books translates into meaningful implementation and practice variation. Certainly, the US marijuana decriminalization literature has demonstrated clearly that differences in laws on the books do not necessarily translate into meaningful differences in arrests [44] .
With knowledge of the legal differences, and whether they translate into real differences in enforcement, it will then be possible to truly understand the impact of these laws on outcomes.
There is an extraordinary policy experiment under way, with little acknowledgement of the regulatory variation that exists across and even within states. The data presented here capture the variations in state MM law at a detailed level, focusing upon particular domains relevant for medical access. In this paper we ignore general areas of these laws that have evolved outside of the need for patient access in 2017, such as cultivation, as the evolution of other state laws (namely legalization) now shape the state-federal conflicts in this space. The substantial variation over time and across jurisdictions in MM dimensions reported here provides an opportunity for rigorous quasiexperimental studies to test state policy approaches to date and illuminate the policy choices ahead. The current diversity of state regulatory strategies provides an ideal opportunity to assess correlations with desired and undesired outcomes; the evaluation of these laws is the logical next step in this line of research, including assessments of how they are implemented and whether these differences across states translate into changes in both behavior and health outcomes.
Our data also provide the material needed for the construction of a medical marijuana policy index. A valid composite indicator of these laws (as has been devised in the alcohol domain, for example [45] ) can only be created when we have some sense of the relative importance of specific dimensions of the policy. While researchers have begun to consider specific elements of medical marijuana laws (e.g. dispensary or home cultivation) they have yet to consider other elements of these laws that work in the tobacco/alcohol field suggest may be relevant when looking for public health effects (e.g. taxation, outlet density, bans). Future research on specific policy components measured in our data can be used to validate the components of an index.
Limitations
The study does not include state laws that permit use of only of CBD oil or low THC marijuana preparations for therapeutic purposes. As of 1 March 2017, 16 states that do not have a comprehensive MM program have passed laws permitting the use of low THC/high CBD products for medical reasons in limited situations [46] . This study only observed the law as written in statutes and regulations. Actual practice may differ from the law on the books. For example, police may not actually enforce restrictions on places of use, or regulatory agencies may lack staff to monitor compliance with packaging rules. Finally, state-level mapping cannot capture more specific requirements that may be imposed at the county or municipal level.
CONCLUSION
Federal scheduling of marijuana as a drug with no therapeutic use has resulted in a patchwork of state laws and hampered research efforts, resulting in a 'medicine' without well-tested efficacy, standardized dosing, safety standards or clear clinical guidelines. MM states have enacted a myriad of laws that mimic some aspects of federal prescription drug and controlled substances laws; they have drawn upon regulatory strategies used to deal with the externalities of alcohol and tobacco and, in some cases, have enacted regulations that go beyond those applied traditionally to medicines (i.e. patient registration, qualifying diagnoses and registration revocation). Only rigorous evaluation research, which the data presented here were created to facilitate, can determine which, if any, of the regulatory strategies states have adopted are succeeding in governing MM as a safe and effective medicine, the use of which is compatible with the public's health and safety.
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